Related Experiment Video
Updated: Apr 23, 2026
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
17.1K
Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban
Muhammed Sherid1, Humberto Sifuentes, Samian Sulaiman
1Section of Gastroenterology and Hepatology, Georgia Regents University, Augusta, Ga., USA.
Digestion
|October 4, 2014
Summary
Gastrointestinal bleeding risk with dabigatran and rivaroxaban is similar, with both showing increased risk in the first 40 days of use. Concomitant dual antiplatelet use with rivaroxaban increased bleeding risk.
Area of Science:
- Pharmacology
- Gastroenterology
- Clinical Medicine
Background:
- Gastrointestinal (GI) bleeding risk associated with direct oral anticoagulants (DOACs) like dabigatran and rivaroxaban requires further investigation.
- Comparative data on GI bleeding incidence between dabigatran and rivaroxaban is limited.
Purpose of the Study:
- To compare the risk of gastrointestinal bleeding between patients taking dabigatran and those taking rivaroxaban.
- To identify factors associated with increased GI bleeding risk in patients on these DOACs.
Main Methods:
- Retrospective analysis of medical records from October 2010 to April 2013.
- Inclusion of 374 patients on either dabigatran or rivaroxaban from two hospitals.
- Multivariate analysis to assess bleeding risk factors.
Main Results:
- Overall GI bleeding incidence was similar between dabigatran (5.3%) and rivaroxaban (4.8%).
- Both dabigatran and rivaroxaban showed a higher bleeding risk within the first 40 days of treatment.
- Dual antiplatelet therapy with rivaroxaban and prior GI bleeding were associated with significantly increased bleeding risk.
Conclusions:
- Dabigatran is not associated with a higher incidence of GI bleeding compared to rivaroxaban.
- The initial 40 days of treatment with either dabigatran or rivaroxaban pose a heightened risk for GI bleeding.
- Risk stratification for rivaroxaban should consider concomitant dual antiplatelet use and history of GI bleeding.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
01:29Venous Thrombosis III: Interprofessional Care
481
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
481
01:12Relative Risk
2.4K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.4K
01:24Esophageal Varices-I: Introduction
2.4K
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
2.4K
01:28Esophageal Varices-II: Clinical Features and Management
872
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
872